agilon health (AGL) Earnings Date & Reports

Key Takeaways

• agilon health reported third quarter 2026 revenue of $1.52 billion, up 5.9% year over year and ahead of the roughly $1.46 billion consensus estimate.
• The company swung to a GAAP profit of $1.97 per diluted share, with net income of $35 million, compared with a net loss of $110 million in the prior-year quarter.
• The medical services expense ratio (MSER), which measures direct medical costs as a share of medical services revenue, improved to 88.5% from 104.0% a year earlier.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) rose to $64 million, versus negative $91 million in the year-ago period.
• Management raised full-year 2026 guidance, lifting adjusted EBITDA to a range of $145 million to $155 million, up from $75 million to $95 million previously.
• Total members on the platform declined 8% to 566,000, reflecting a deliberate focus on profitability over growth.
• For more detail on agilon health, you can explore its Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• To uncover broader market opportunities, explore Trending AI Robots and see how AI-driven tools scan for potential trade ideas.

Earnings Context and Why It Matters

agilon health partners with independent primary care physician groups to shift senior care from fee-for-service to value-based, risk-bearing models, primarily through Medicare Advantage. Its profitability hinges on controlling medical costs within capitated (per-member, fixed) payments, so the MSER is the single most important signal for investors. After several quarters of heavy losses driven by elevated medical cost trends, the third quarter of 2026 marks a pivotal test of whether management's cost discipline and contracting strategy can translate into sustainable profitability. With revenue growth moderating and membership shrinking, the market is focused less on scale and more on whether agilon can earn more per member without sacrificing long-term growth.

Reported Results

For the third quarter ended September 30, 2026, agilon health reported total revenue of $1.52 billion, a 5.9% increase from $1.44 billion a year earlier and above the consensus estimate of approximately $1.46 billion. GAAP net income reached $35 million, or $1.97 per diluted share, a sharp turnaround from a net loss of $110 million in the prior-year period and well above analyst expectations for a loss.

The headline operating improvement was the MSER, which fell to 88.5% from 104.0%, moving decisively below 100% and indicating the company spent less on member care than it collected in capitated revenue. Adjusted EBITDA swung to $64 million from negative $91 million a year earlier. Membership, however, contracted: total members fell 8% to 566,000, including 454,000 Medicare Advantage members (down 10%) and 112,000 ACO (accountable care organization) model beneficiaries.

Management also raised full-year 2026 guidance, now projecting adjusted EBITDA of $145 million to $155 million, revenue of $5.87 billion to $5.89 billion, and an MSER of 90.3% to 90.5%.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters covering industry, market capitalization, technical indicators, price patterns, and performance metrics. By automating the screening process, the tool helps identify trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. Whether you are researching names like agilon health or scanning entire sectors, the AI Screener can streamline your workflow and surface actionable ideas.

Market Reaction and Investor Sentiment

The third quarter results were received positively, with the stock advancing in the immediate aftermath of the release as investors digested the swing to profitability and the upwardly revised full-year outlook. The decisive improvement in the MSER and the jump in adjusted EBITDA addressed the central concern that had weighed on agilon health's valuation: whether its value-based care model could generate consistent profits. The earnings beat was substantial relative to consensus, but the market is also weighing the 8% decline in total membership, which signals that margin gains are currently being achieved on a smaller base. Management framed the contraction as intentional, tied to disciplined contracting and previously announced market exits, which helped support a constructive near-term reaction.

Forward Outlook and Key Factors to Monitor

Following this earnings event, investors will focus on whether the margin recovery is durable. Management attributed part of the MSER improvement to favorable claims development in the first half of 2026, a benefit that may not fully recur. Watching future quarters will reveal whether the improved cost trends are structural or partly one-time in nature.

Membership trends remain a key watch item. The company expects ACO membership to grow roughly 40% to 50% in 2027, largely through the Medicare Shared Savings Program, which could reaccelerate growth without immediately exposing the company to the same medical cost risk. The pace and economics of these additions will matter for the revenue outlook.

Finally, 2027 payer contracting is underway and will address roughly half of the company's book of business. The terms agilon secures, along with ongoing medical cost trends and risk-adjustment performance, will shape both the MSER and adjusted EBITDA trajectory in the year ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations